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Background: The  mcr-1  gene is a transferable resist-
ance determinant against colistin, a last-resort anti-
microbial for infections caused by multi-resistant 
Gram-negatives. Aim: To study carriage of antibiotic-
resistant bacteria in healthy school children as part 
of a helminth control and antimicrobial resistance 
survey in the Bolivian Chaco region. Methods: From 
September to October 2016 we collected faecal sam-
ples from healthy children in eight rural villages. 
Samples were screened for  mcr-1- and  mcr-2  genes. 
Antimicrobial susceptibility testing was performed, 
and a subset of 18 isolates representative of individuals 
from different villages was analysed by whole genome 
sequencing (WGS). Results: We included 337 children 
(mean age: 9.2 years, range: 7–11; 53% females). The 
proportion of  mcr-1  carriers was high (38.3%) and 
present in all villages; only four children had previ-
ous antibiotic exposure. One or more  mcr-1-positive 
isolates were recovered from 129 positive samples, 
yielding a total of 173 isolates (171  Escherichia coli, 
1  Citrobacter europaeus, 1  Enterobacter hormaechei). 
No mcr-2 was detected. Co-resistance to other antimi-
crobials varied in  mcr-positive  E. coli. All 171 isolates 
were susceptible to carbapenems and tigecycline; 
41 (24.0%) were extended-spectrum β-lactamase 
producers and most of them (37/41) carried  blaCTX-
M-type genes. WGS revealed heterogeneity of clonal 
lineages and  mcr-genetic supports. Conclusion: This 
high prevalence of  mcr-1-like carriage, in absence of 
professional exposure, is unexpected. Its extent at 
the national level should be investigated with priority. 
Possible causes should be studied; they may include 
unrestricted use of colistin in veterinary medicine and 
animal breeding, and importation of  mcr-1-positive 
bacteria via food and animals.
Background
The  mcr-1  gene is a transferable colistin resistance 
determinant that was first described among entero-
bacterial strains isolated from animals and humans 
in China. The gene encodes a phosphoethanolamine 
transferase that modifies the colistin target by addition 
of phosphoethanolamine to the 1’ or 4’ phosphate group 
of lipid A, which reduces its affinity to colistin [1,2]. 
Discovery of  mcr-1  was considered highly alarming, 
given the role that colistin has recently regained as 
a last-resort antibiotic for treatment of infections 
caused by multi-resistant Gram-negative patho-
gens such as carbapenem-resistant Enterobacterales 
and Acinetobacter baumannii [1,3].
Subsequent to its discovery, several studies 
have revealed a global distribution of  mcr-1, with 
an overall higher prevalence among  Escherichia 
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coli and Salmonella enterica, and occasional occurrence 
in other enterobacterial species. Most  mcr-1-positive 
strains were of animal origin, and farm animals were 
identified as the principal reservoir of mcr-1 genes [1,4]. 
Investigation of archival strains dated the presence 
of  mcr-1  back to at least the 1980s [5]. As with other 
resistance genes, minor allelic variants of  mcr-1  have 
been detected [6]. More recently, additional trans-
ferable  mcr  genes (mcr-2,  mcr-3,  mcr-4,  mcr-5, mcr-
6, mcr-7 and mcr-8) have been reported, for which the 
global epidemiology remains to be clarified [7-13].
In South America, mcr-1 genes have been reported from 
several countries in isolates from humans, animals 
Figure 1
Geographical locations of the surveyed communities and the proportion of mcr-1-positive samples, Chaco, Boliva, 
September–October 2016 (n = 8 communities)
Charagua
Villa Montes
Yacuiba
Gutierrez
Lagunillas
La Paz
Sucre
BOLIVIA
PALMAR CHICO 
19/39 (48.7%; 95% CI: 33– 64.4)
SAN ANTONIO DEL PARAPETÍ 
9/47 (19.1%; 95% CI: 7.9–30.3)
CHIMEO 
16/39 (41.0%; 95% CI: 25.6–56.4)
TARAIRÍ 
33/41 (80.5%; 95% CI: 68.4–92.6)
CAPIRENDITA 
4/16 (25.0%; 95% CI: 3.8–46.2)
PALMARITO 
13/46 (28.3%; 95% CI: 15.3–41.3)
IVAMIRAPINTA 
17/67 (25.4%; 95% CI: 15–35.8)
TETA PIAU / KURUPAITY 
18/42 (42.9%; 95% CI: 27.9–57.9)
Santa Cruz de la Sierra
Tarĳa
CI: confidence interval.
The surveyed communities are located in the Bolivian Chaco, in rural areas of five municipalities (indicated with stars). For each community, 
the proportion of mcr-1-positive samples versus the total number of collected samples is reported, along with 95% CI. Major Bolivian cities are 
indicated by circles.
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and food [14-27]. Recently, the Pan American Health 
Organisation (PAHO) section of the World Health 
Organization (WHO) recommended to implement and 
strengthen surveillance and epidemiological investiga-
tion of plasmid-mediated transferable colistin resist-
ance in its Member States [14]. In Bolivia,  mcr-1  has 
thus far been reported in a  Citrobacter braakii  that 
was isolated from a ready-to-eat food sample [21], as 
well as in a few clinical isolates of E. coli referred from 
various departments to the National Institute of Health 
Laboratories (INLASA) (data not shown).
During the last two decades we carried out several sur-
veillance studies in the Bolivian Chaco region, docu-
menting a high prevalence of resistance to old and 
more recent antibiotics in commensal and pathogenic 
bacteria from humans [21,28-32].
In 2016, a new surveillance study was carried out in 
a population of healthy school children from several 
rural communities in this region to investigate the 
prevalence of intestinal parasites and the carriage of 
antibiotic-resistant bacteria. Here we report about an 
unexpected and high rate of faecal carriage of  mcr-
1-positive Enterobacterales in this population.
Methods
Study population and setting
The study population consisted of healthy school chil-
dren living in eight rural communities of the Chaco 
region, in south-eastern Bolivia (between longitude 
63°66 and 63°18 east and latitude 19°49 and 21°88 
south, Figure 1). In these communities, the population 
lives in houses mostly constructed of mud and sticks, 
with packed earth floors and straw or corrugated metal 
roofs. There is no wired electricity and no sewage sys-
tem. The main water sources are small ponds, in which 
animals also bathe and drink, and outdoor taps. The 
economy is mostly based on subsistence farming and 
local animal husbandry.
In each community, children were selected among 
those attending primary school, starting from the 
third year and possibly including the upper years, to 
achieve a number of ca 50 individuals per site when-
ever possible. This sample size corresponded to that 
recommended by WHO for cluster sampling in helminth 
control programmes in healthy school children [33].
Previous use of antibiotics during the last 15 days 
was investigated by a questionnaire administered to 
parents.
Laboratory analyses
Screening for mcr-1- and mcr-2-positive strains in faecal 
samples
One faecal sample for each child was collected during 
a two-month period from September to October 2016; 
the samples were transferred to the Laboratories of 
Camiri or Villa Montes Hospitals within 6 hours and 
were plated onto MacConkey agar. After incubation at 
35 °C for 24 hours, the bacterial growth (representative 
of the total enterobacterial microbiota) was collected 
with a sterile swab in an Amies transport medium 
and was shipped to Italy. Each sample was then sub-
cultured on MacConkey agar again, and the bacterial 
growth was resuspended in Brain Heart Infusion broth 
plus 20% (v/v) glycerol and stored at -70 °C pending 
further analyses.
To screen for the presence of mcr-1- and mcr-2-positive 
strains, the preserved suspensions of total enterobac-
terial microbiota were thawed and 10 μl were inocu-
lated onto McConkey supplemented with colistin (2 
mg/L, MCC medium). After incubation at 35 °C for 24 
hours, a loopful of the bacterial growth (taken either 
from confluent growth or from isolated colonies of 
Table 1
Features of the study population, stratified by mcr-1-positive and -negative children, Chaco, Bolivia, September–October 
2016
Characteristics
Total 
 
(n/N)
%
mcr-1-negative 
 
(n/N)
%
mcr-1-positive 
 
(n/N)
% P value
Sex
Male 158/337 47 100/208 48 58/129 45
0.58
Female 179/337 53 108/208 52 71/129 55
Age (years)
Mean (95% CI) 9.3 (9.1–9.4) NA 9.3 (9.1–9.5) NA 9.2 (9.0–9.5) NA
0.81
Median (IQR) 9 (8–10) NA 9 (8–10) NA 9 (8–10) NA
Prior antibiotic usea 4/337 1 3/208 1 1/129 1 0.58
CI: confidence interval; IQR: interquartile range; NA: not applicable.
aIn the last 15 days.
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different morphologies) was resuspended in 300μl of 
normal saline, and half of the bacterial suspension was 
used to prepare a crude DNA extract by heating at 99 °C 
for 15 minutes. The crude extracts were then screened 
for the presence of mcr-1 and mcr-2 genes by real-time 
(RT) PCR, as described previously [34]. In the case of a 
positive result, the remaining bacterial suspension was 
used to inoculate the MCC medium to obtain isolated 
colonies, and all isolated colonies of different morphol-
ogy were then tested for the presence of mcr genes by 
RT-PCR. The mcr-positive isolates were identified using 
MALDI-TOF mass spectrometry (Vitek MS, bioMérieux, 
Marcy-l’Etoile, France).
When a sample yielded two or more  mcr-1-positive 
isolates of the same species, clonal relatedness of 
the isolates was investigated by random amplifica-
tion of polymorphic DNA (RAPD) profiling, as described 
previously [35]. The three  mcr-positive isolates that 
were colistin susceptible were subjected to  mcr  gene 
amplification and sequencing using previously 
described primers and conditions [34].
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was carried out 
using reference broth microdilution [36]. Minimum 
inhibitory concentration (MIC) results were interpreted 
according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) clinical breakpoints 
[36].
Analysis of extended-spectrum β-lactamases
All isolates showing a ceftazidime and/or cefotaxime 
MIC > 1 mg/L were screened for extended-spectrum 
β-lactamases (ESBL) production by a combination 
disk test using ceftazidime and cefotaxime as sub-
strates and clavulanic acid as an inhibitor [37]. ESBL-
positive isolates by phenotypic testing were subjected 
to RT-PCR for the detection of  blaCTX-M  ESBL genes, as 
described previously [38].
Whole genome sequencing
A subset of 18  mcr-1-positive isolates were subjected 
to whole genome sequencing (WGS) analysis. This 
subset comprised two  E. coli  isolates per community: 
from randomly selected individuals co-colonised 
by two different  mcr-1-positive  E. coli  or from two 
randomly selected individuals if co-colonisations were 
not detected and the two non-E. coliisolates bore mcr-
1. For the latter, species identification was carried 
out by the analysis of housekeeping genes [39,40]. 
Bacterial genomic DNA of these 18 selected  mcr-pos-
itive isolates, extracted using the phenol-chloroform 
method [41], was subjected to WGS with a MiSeq 
platform (Illumina, Inc., San Diego, California, United 
States (US)) using a 2x300 paired-end approach. 
Raw reads were assembled using SPAdes 3.5 [42]. An 
average of 120 contigs per strain was obtained, with 
an average N50 of 163 Kb. Draft genomes have been 
deposited in the National Center for Biotechnology 
Information (NCBI) WGS database under the BioProject 
PRJNA427943 (accession numbers: PQTO00000000; 
PQTN00000000; PQTM00000000; PQTL00000000; 
PQTK00000000; PQTJ00000000; PQTI00000000; 
PQTH00000000; PQTG00000000; PQTF00000000; 
PQTE00000000; PQTD00000000; PQTC00000000; 
PQTB00000000; PQTA00000000; PQSZ00000000; 
PQSY00000000; PQSX00000000). Resistance genes 
and plasmid content were investigated using the 
ResFinder and PlasmidFinder tools available at the 
Center for Genomic Epidemiology at  https://cge.cbs.
dtu.dk/services/ResFinder/. Clonal relatedness was 
investigated by in silico determination of the multilo-
cus sequence typing (MLST) profile obtained by the 
MLST 1.8 software (available at  https://cge.cbs.dtu.
dk/services/MLST/) using the assembled WGS as input 
data.
Statistical analysis
Statistical analysis of the data was performed with 
STATA 11.0 (StataCorp, College Statio, Texas, US). 
Frequencies and percentages with 95% confidence 
intervals (CI) for categorical variables, medians and 
interquartile ranges (IQR) for continuous variables 
were calculated. Mann–Whitney test was used to com-
pare median age. Chi-squared test was used to inves-
tigate the association of  mcr-1  carriage with sex and 
prior antibiotic use. Results were considered signifi-
cant when the p value was ≤ 0.05.
Ethical statement
Written informed consent was always obtained 
from parents or legal guardians. The investigation 
was planned and carried out within a collaboration 
Table 2
Susceptibility of mcr 1-positive Escherichia coli isolates to various antimicrobials, Chaco, Bolivia, September–October 2016 
(n = 171)
AMC PTZ CAZ CTX FEP MEM ERT GEN CIP TIG COL Total
n % n % n % n % n % n % n % n % n % n % n % n %
72 42.1 171 100 130 76.0 128 74.9 130 76.0 171 100 171 100 138 80.7 62 36.3 171 100 168 1.7 171 100
AMC: amoxicillin/clavulanate (clavulanate at fixed concentration of 4 mg/L); CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin; CTX: 
cefotaxime; ERT: ertapenem; FEP: cefepime; GEN: gentamicin; MEM: meropenem; PTZ: piperacillin/tazobactam (tazobactam at fixed 
concentration of 4 mg/L); TIG: tigecycline.
Numbers and percentages of susceptible isolates are given.
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Table 3
Features of mcr-1-positive isolates subjected to whole genome sequencing analysis, Chaco, Bolivia, September–October 2016 
(n = 18)
Community Isolate code
Subject 
code Species
Additional 
resistance 
trait(s)a
Acquired resistance genesb STc mcr variant and genetic contextd
mcr contig 
size (bp)
Palmarito
12A 1 Escherichia coli AMC; GEN; CIP
blaTEM-1B; aac (3)-IV; aph (4)-
Ia; fosA3; floR; qnrB19; tet(A) 48 mcr-1-pap(IncI2) 61,600
12B 1 E. coli GEN; CIP
blaTEM-1B; aac (3)-IV; 
aph(3’)-Ia; aph (4)-Ia; strA; 
strB; catA1; floR; oqxA; oqxB; 
sul2; tet(A)
744 mcr-1-pap(IncI2) 60,992
Ivamirapinta
155A 2 E. coli FSe ND 10 mcr-1-pap(IncI2) 60,547
155B 2 E. coli AMC; CIP
blaTEM-1A; aadA1; aadA2; strA; 
strB; cmlA1; floR; qnrB19; sul2; 
sul3; tet(A); dfrA8
206 mcr-1-unkf 2,943
Tetapiau/Kurupaity
86A 3 E. coli AMC; CIP blaTEM-1B; strA; strB; floR; qnrB19; sul2; tet(A); dfrA1 2,705 mcr-1-unk
f 2,942
86B 3 E. coli AMC; CIP
blaTEM-1B; aadA1; aadA2; strA; 
strB; cmlA1; floR; sul1; sul2; 
sul3; tet(A); tet(B); dfrA1; dfrA12
2,936 mcr-1.5-pap-ISApl1(IncHI1) 13,7897
67A 4 Citrobacter europaeus AMC qnrB19; qnrB28 NA mcr-1-pap(IncI2) 60,321
San Antonio del 
ParapetÍ
173A 5 E. coli
AMC; CIP; 
GEN; CAZ; 
CTX; FEP; 
(ESBL)
blaCTX-M-55; aadA1; aadA2; 
aadA5; rmtB; fosA3; cmlA1; floR; 
qnrB19; sul3; tet(A); dfrA17
1,286 mcr-1-unkf 6,134
173B 5 E. coli
AMC; CIP; 
GEN; CAZ; 
CTX; FEP; 
(ESBL)
blaCTX-M-55; blaTEM-1B; 
aadA1; aadA2; rmtB; cmlA1; 
floR; qnrB19; sul3; tet(A)
1,286 mcr-1-unkf 2,863
TarairÍ
224A 6 E. coli AMC
aadA1; aadA2; strA; strB; 
cmlA1; floR; qnrB19; sul2; sul3; 
tet(A); tet(B); dfrA14
2,705 mcr-1-pap(IncI2) 59,561
224B 6 E. coli AMC; CIP
blaTEM-1B; aadA1; aadA2; strA; 
strB; cmlA1; floR; QnrB19; sul2; 
sul3; tet(A); tet(B); dfrA14
7,570
∆ISApl1-
mcr-1-pap-
ISApl1(IncHI1)
52,737
Palmar Chico
306A 7 E. coli AMC blaTEM-1B; aadA5; strA; strB; sul1; sul2; dfrA17 69 mcr-1-pap(IncI2) 63,921
306B 7 E. coli AMC; CIP blaTEM-1B; blaOXA-1; aadA1; sul1; tet(X) 10 mcr-1-pap(IncI2) 64,425
301B 8 Enterobacter hormaechei FS
e ND - mcr-1-pap(IncI2) 63,943
Capirendita
286A 9 E. coli AMC blaTEM-1B; aadA1; floR; sul3; tet(A); tet(C); dfrA1 117 mcr-1-pap(IncI2) 59,748
295B 10 E. coli FSe ND 711 mcr-1-pap(IncI2) 56,317
Chimeo
274A 11 E. coli AMC; GEN; CIP
blaTEM-1B; aac (3)-IV; aadA1; 
aadA2; aph(3’)-Ia; cmlA1; floR; 
qnrB19; sul2; sul3; tet(A); 
tet(M); dfrA12
7,571 mcr-1-unkf 2,943
274B 11 E. coli
AMC; CAZ; 
CTX; FEP 
(ESBL)
blaCTX-M-55; blaTEM-1B; 
blaOXA-10; aac(6‘)Ib-cr; aacA4; 
aadA1; strA; strB; fosA3; cmlA1; 
floR; qnrB19; qnrVC4; sul2; 
tet(A); dfrA14
3,056 mcr-1-pap(IncI2) 60,652
AMC: amoxicillin/clavulanate (clavulanate at fixed concentration of 4 mg/L); CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin; CTX: 
cefotaxime; ESBL: extended-spectrum β-lactamase; FEP: cefepime; FS: fully susceptible; GEN: gentamicin; NA: not applicable; ND: none 
detected; ST: sequence type; unk: unknown.
aAll isolates were resistant to colistin; additional resistance traits referred to the panel of tested drugs reported in Table 2.
bAcquired resistance genes as determined by analysis with the ResFinder software.
cSequence-types were assigned using the Warwick scheme (http://enterobase.warwick.ac.uk/species/index/ecoli).
dIf the gene was linked with a known plasmid backbone, the plasmid replicon type is reported in brackets.
eThe isolate was susceptible to all tested agents except colistin.
fIn these cases it was not possible to reveal the nature of flanking regions due to the presence of repeated sequences flanking the gene.
For each isolate, the epidemiological data, additional resistance profile, acquired resistance genes content, sequence type and mcr genetic 
context are reported.
6 www.eurosurveillance.org
agreement between the Ministry of Health of the 
Plurinational State of Bolivia and the University of 
Florence, Italy, and with the support of the Guaraní 
political organisation (Asamblea del Pueblo Guaraní). 
Ethical approval for the study was obtained from the 
above-mentioned institutions (see Acknowledgements 
section).
Results
Faecal specimens were obtained from 337 healthy 
school children in eight rural communities of the 
Bolivian Chaco region (Figure 1). Children (179 females; 
53%;) were aged 7 to 11 years (mean: 9.2 years). 
Previous antibiotic exposure was only reported for four 
children.
mcr-1 carriage
All 337 samples of enterobacterial microbiota yielded 
some growth (from scanty to vigorous) on the MCC 
medium, and 129 (38.3%) yielded a positive result 
for  mcr-1. Positive samples were detected in children 
from each village, although at variable rates (range: 
19.1–80.5%;  Figure 1). No  mcr-2  genes were detected. 
One or more mcr-1-positive isolates were recovered from 
each of the 129 samples, yielding a total of 173 posi-
tive isolates, including 171 E. coli, one Citrobacter spp. 
and one Enterobacter spp.. Multiple mcr-1-positive iso-
lates from the same sample consisted of either two or 
three  E. coli  isolates of different colonial morphology 
and RAPD profile (in 32 and 5 samples, respectively), or 
in an E. coli plus an Enterobacter spp. (in one sample).
No differences were found in the demographic charac-
teristics, sex or age, of children carrying mcr-1-positive 
Enterobacterales or children without  mcr-1  carriage 
(Table 1), nor were there any differences in the living 
conditions of the communities with different propor-
tions of carriers (data not shown).
Antimicrobial susceptibility of mcr-1-positive 
isolates
Colistin susceptibility testing showed that the major-
ity (n = 170; 98.3%) of the  mcr-1-positive isolates were 
resistant to colistin (MIC range: 4–> 8 mg/L), while 
only three  E. coli  (from different villages) were colis-
tin-susceptible (all with an MIC of 2 mg/L) (Table 2). 
Sequencing of  mcr  amplicons from the latter isolates 
showed identity with  mcr-1, suggesting that the colis-
tin susceptible phenotype was not due to mutations 
inactivating the gene. Variable resistance rates to 
other antimicrobial agents were observed, including 
fluoroquinolones, expanded-spectrum cephalospor-
ins, β-lactamase plus inhibitor combinations and gen-
tamicin. All isolates were susceptible to carbapenems 
and tigecycline (Table 2).
Diversity of the mcr-1-positive isolates
WGS analysis of the subset of 18  mcr-1-positive iso-
lates confirmed the identification of the two non-E. 
coli isolates as Citrobacter europaeus and Enterobacter 
hormaechei, respectively (Table 3), two species in 
which mcr-1 was not previously reported.
In silico MLST analysis of the 16 E. coli isolates revealed 
a considerable diversity, with only a few isolates from 
different villages belonging to the same sequence type 
(ST). All but one of the couples isolated from the same 
individual belonged to different STs (Table 3).
Analysis of the acquired resistance genes showed a 
remarkable diversity and a variety of patterns (Table 
3). The number of known acquired resistance genes 
varied from 0 to 16 (median: 9). Overall, the resistance 
gene content was consistent with the susceptibility 
profile. The three ESBL-positive E. coli  isolates carried 
the blaCTX-M-55 variant previously reported in Bolivia [30].
Analysis of the  mcr-1  carrying contigs revealed that 
in 13 isolates the  mcr-1  gene was linked to backbone 
regions typical of IncI2 or IncHI1 plasmids, suggesting 
a plasmid location, with some plasmid diversity. In the 
remaining five isolates, it was not possible to deter-
mine the nature of flanking regions due to the presence 
of repeated sequences flanking the gene (Table 3).
Discussion
Our study revealed a very high prevalence of carriage 
of mcr-1-positive strains among healthy children living 
in rural communities of the Bolivian Chaco. Carriage 
of  mcr-1-positive strains in healthy humans has been 
investigated in a limited number of studies, mostly from 
Asian countries [41-53]. The prevalence rates detected 
in such studies have usually been low (< 5%), except in a 
group of chicken farmers from Vietnam, where a 34.7% 
carriage rate of mcr-1-positive E. coli was detected and 
attributed to professional exposure to  mcr-1-positive 
animals [45]. Therefore, to our best knowledge, we pre-
sent the highest rate of mcr-1 carriage thus far reported 
in healthy humans.
In our study, professional exposure could be excluded 
as a reason for the high prevalence of  mcr-1  carriage, 
as well as human use of colistin. Overall, only four 
children had prior exposure to antibiotics and the use 
of colistin in Bolivia is occasional and limited to infec-
tions by some multi-drug resistant pathogens in large 
urban hospitals (data not shown). However, colistin is 
available with no restrictions for veterinary use and 
in animal breeding [54], and we hypothesise that this 
could have played a major role in the selection of colis-
tin-resistant strains in the animal population and the 
environment. Moreover, the introduction of  mcr-posi-
tive strains via imported food and/or food-producing 
animals from countries where their prevalence was 
found to be high (e.g. Brazil) [15,22] could also repre-
sent a source of such strains. Poor sanitation and close 
contact with animals, which characterise the studied 
setting, may lead to a high level of environmental con-
tamination and facilitate cross-transmission of colistin-
resistant strains and colistin resistance genes between 
different environments, resulting in a high prevalence 
in humans who are not directly exposed to the drug.
In our case, only a minority of the  mcr-positive iso-
lates showed resistance to other antimicrobials, and 
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no carbapenem resistance was detected, leaving a 
number of therapeutic options in case of infection. 
However, the potential risk of spread of the mcr-1 gene 
to extensively resistant isolates through transferable 
plasmids mechanisms should not be underestimated.
Genomic analysis of a subset of the  mcr-1-positive  E. 
coli  isolates, representative of different communities 
and of different isolates from the same child, revealed 
a remarkable heterogeneity in terms of clonal lineages 
and genetic supports. Therefore, the observed 
epidemiological scenario could not be ascribed to the 
expansion of a single  mcr-1-positive clone, nor even 
to the spread of a single plasmid. The diversity of the 
genetic background of the mcr-1 genes underlined the 
ability of this gene to transfer itself among different 
clones (and even different species) and plasmids. 
Interestingly, we detected for the second time in South 
America the  mcr-1.5  variant, previously described in 
an E. colistrain from Argentina [23].
Our study has some limitations. First, the presence 
of animal or environmental reservoirs of  mcr-positive 
isolates and the direct transmission between humans 
and animals/environment could not be demonstrated, 
since we did not collect any samples from animals or 
the environment. Second, apart from  mcr-2, we did 
not search for other recently described  mcr-variants 
that could be responsible for resistance observed 
in other isolates. Third, the study was designed as a 
cross-sectional survey, in which one sample from each 
individual was collected. It would be interesting to 
investigate the prevalence of  mcr-1  carriage in adults 
and the duration of carriage over time to understand 
if and how much humans could represent a major 
reservoir in this setting. It would also be interesting to 
further characterise, in more detail, the plasmid sup-
ports of the  mcr-1  and other resistant determinants. 
Investigations on these aspects are underway.
In conclusion, our findings prompt the need to rap-
idly monitor the extent of human and animal carriage 
rates and environmental contamination by  mcr  genes 
with a one-health approach, and to introduce policies 
banning the non-therapeutic use of colistin. This was 
also recently highlighted by the PAHO/WHO, which 
encouraged the implementation of animal-human sur-
veillance, as well as actions to prevent and control 
the spread of  mcr-positive microorganisms, such as 
the monitoring of colistin use in human food produc-
tion [14]. In Europe, knowledge of  mcrcarriage among 
healthy individuals is still limited [47,53]. While avail-
able data suggest a very low occurrence, it will be inter-
esting to study human and animal carriage rates and 
environmental contamination in different countries and 
settings.
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